IDH2 and acute myeloid leukemia: Similarly, enasidenib monotherapy in R/R AML resulted in an overall response rate of 38.8% (including MLFS and partial remission), of which 12% achieved IDH2-MRDneg, associated with a significant survival benefit (median OS 22.9 months vs. 8.8 months, p = 0.0153) [85].